OTraces has developed a disruptive technology using math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer diagnostics. By using these techniques to access the active proteins found in the tumor microenvironment (TME) with, for the first time, simple and cost-effective blood based-tests, OTraces has solved the problem of deciphering biomarker activity within the TME, which has come to be recognized and accepted in science as a vast storehouse of diagnostic content exceeding the tumor itself. It is the only blood test known to determine tumor status and progression. In upcoming news, OTraces is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City. Learn more and register to attend the conference at www.nyconcologyconference.com.